Constellation Pharmaceuticals Inc (NASDAQ:CNST) CFO Emma Reeve Sells 5,521 Shares of Stock

Constellation Pharmaceuticals Inc (NASDAQ:CNST) CFO Emma Reeve sold 5,521 shares of Constellation Pharmaceuticals stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.06, for a total transaction of $193,566.26. Following the sale, the chief financial officer now owns 1,103 shares of the company’s stock, valued at $38,671.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Emma Reeve also recently made the following trade(s):

  • On Tuesday, February 11th, Emma Reeve sold 8,642 shares of Constellation Pharmaceuticals stock. The stock was sold at an average price of $35.04, for a total transaction of $302,815.68.

CNST opened at $36.06 on Friday. The company’s 50-day simple moving average is $38.67 and its two-hundred day simple moving average is $24.33. Constellation Pharmaceuticals Inc has a 52-week low of $6.01 and a 52-week high of $59.49. The company has a debt-to-equity ratio of 0.81, a quick ratio of 5.19 and a current ratio of 5.19. The stock has a market capitalization of $1.48 billion, a P/E ratio of -11.48 and a beta of 6.93.

Several research analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price (up from $17.00) on shares of Constellation Pharmaceuticals in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Constellation Pharmaceuticals in a research report on Tuesday, December 10th. Zacks Investment Research downgraded shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Royal Bank of Canada upped their target price on shares of Constellation Pharmaceuticals to $42.00 and gave the stock a “positive” rating in a research report on Thursday, November 7th. Finally, SunTrust Banks assumed coverage on shares of Constellation Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $44.09.

Several large investors have recently modified their holdings of the company. Rhumbline Advisers increased its holdings in Constellation Pharmaceuticals by 2.4% in the 4th quarter. Rhumbline Advisers now owns 20,331 shares of the company’s stock worth $958,000 after acquiring an additional 471 shares in the last quarter. Bank of Montreal Can increased its holdings in Constellation Pharmaceuticals by 43.0% in the 4th quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock worth $91,000 after acquiring an additional 582 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Constellation Pharmaceuticals by 43.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock worth $73,000 after acquiring an additional 666 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Constellation Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, UBS Group AG increased its holdings in Constellation Pharmaceuticals by 15.9% in the 4th quarter. UBS Group AG now owns 13,905 shares of the company’s stock worth $655,000 after acquiring an additional 1,912 shares in the last quarter. Hedge funds and other institutional investors own 49.91% of the company’s stock.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Read More: Hedge Funds Explained

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.